Jackson Square Capital LLC Trims Stock Position in AbbVie Inc. $ABBV

Jackson Square Capital LLC cut its holdings in AbbVie Inc. (NYSE:ABBV) by 12.9% during the 3rd quarter, Holdings Channel reports. The firm owned 15,334 shares of the company’s stock after selling 2,275 shares during the period. Jackson Square Capital LLC’s holdings in AbbVie were worth $3,550,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ABBV. Baker Tilly Wealth Management LLC raised its position in shares of AbbVie by 4.9% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 4,828 shares of the company’s stock worth $1,118,000 after purchasing an additional 226 shares during the last quarter. Meadowbrook Wealth Management LLC acquired a new position in shares of AbbVie in the third quarter worth $3,841,000. Lifestyle Asset Management Inc. lifted its position in shares of AbbVie by 9.6% in the third quarter. Lifestyle Asset Management Inc. now owns 1,541 shares of the company’s stock valued at $357,000 after acquiring an additional 135 shares in the last quarter. Brady Family Wealth LLC boosted its stake in shares of AbbVie by 7.2% during the third quarter. Brady Family Wealth LLC now owns 6,532 shares of the company’s stock valued at $1,512,000 after acquiring an additional 440 shares during the last quarter. Finally, Centurion Wealth Management LLC increased its position in AbbVie by 57.2% during the 3rd quarter. Centurion Wealth Management LLC now owns 2,368 shares of the company’s stock worth $548,000 after purchasing an additional 862 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABBV. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Wells Fargo & Company raised their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Piper Sandler reissued an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Finally, Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Stock Up 2.1%

Shares of ABBV opened at $227.44 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company’s fifty day moving average is $226.63 and its two-hundred day moving average is $211.14. The firm has a market cap of $401.98 billion, a PE ratio of 172.30, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company posted $3.00 EPS. The business’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.